Fresh analysis reveals that patients who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional lifestyle regimens.
Research printed in a major medical journal shows that while obese individuals frequently drop a large proportion of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals buying such drugs should be cognizant of the potential of fast rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a return to starting mass in about a year and a half.
Comparing Therapies
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists point out that people who lose weight through lifestyle changes alone typically see a less rapid weight regain—approximately 100 grams monthly—after stopping.
Understanding the Fast Rebound
Nutrition scientists believe the mode of action of the drugs accounts for the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the body to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Disease?
Medical guidelines recommend the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, considering the high risk of weight regain, the therapy should be considered life-long.
This opinion is supported by drug manufacturers, who state that the results "emphasize the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
People who have discontinued the medication explain a powerful resurgence of cravings.
"I experienced a trigger activating and you become extremely hungry," recalled a patient.
This difficulty is worsened if patients have not adopted permanent dietary or behavioural changes during treatment.
Growing Use
Figures show that a significant number of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is more common among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers caution that while the jabs are potent tools for shedding pounds, they are not a permanent fix and maintained weight loss hinges on integrated lifestyle changes.
